(Vax-Before-Travel)
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) announced today that it has approved Valneva SE’s IXCHIQ® vaccine chikungunya vaccine (live) to protect adults against chikungunya disease.
On February 4, 2025, Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, released a press release stating, “Patient safety is our top priority, which is why I am pleased to confirm the approval of the first vaccine in the UK to protect adults 18 years and older against Chikungunya disease.”
The IXCHIQ® vaccine has already been approved in the United States and Europe.
This is a developing story, and this article will be updated.
Visited 1 times, 1 visit(s) today
